Neuroleptic malignant syndrome

Common Name(s)

Neuroleptic malignant syndrome

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroleptic malignant syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Neuroleptic malignant syndrome" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Neuroleptic malignant syndrome" returned 109 free, full-text research articles on human participants. First 3 results:

Recurrence of neuroleptic malignant syndrome.
 

Author(s): Leticia González-Blanco, Hilario García-Prada, Susana Santamarina, Luis Jiménez-Treviño, Julio Bobes

Journal: Actas Esp Psiquiatr. ;41(5):314-8.

 

Neuroleptic malignant syndrome (NMS) is a rare idiosyncratic reaction associated with the use of neuroleptics that has an incidence of 0.02 to 3% among patients taking these drugs. This is a very serious complication with a mortality rate that reaches 10-20%. It is therefore very ...

Last Updated: 7 Oct 2013

Go To URL
Delirium followed by neuroleptic malignant syndrome in rehabilitation setting. Is it anger reaction before discharge?
 

Author(s): Rafat M Al Owesie, Asirvatham Alwin Robert

Journal:

 

Delirium and neuroleptic malignant syndrome (NMS) are two uncommon syndromes that are often unrecognized or misdiagnosed by the primary physicians as functional psychiatric disorders. The infrequency and the heterogeneity of clinical manifestation, progression and outcome with which ...

Last Updated: 6 Sep 2013

Go To URL
Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report.
 

Author(s): Shun Kishimoto, Kumi Nakamura, Toshiyuki Arai, Ogino Yukimasa, Norihiko Fukami

Journal: J Anesth. 2013 Oct;27(5):768-70.

 

A 75-year-old man who had undergone left upper lobectomy of the lung exhibited fever and insomnia on postoperative day (POD) 1 and muscle rigidity, autonomic instability, and somnolence on POD2 after epidural administration of droperidol and withdrawal of oral etizolam. He had not ...

Last Updated: 11 Oct 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Neuroleptic malignant syndrome" returned 18 free, full-text review articles on human participants. First 3 results:

[Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review].
 

Author(s): Zoltán Asztalos, Luca Egervári, Gábor Andrássy, Gábor Faludi, Ede Frecska

Journal: Neuropsychopharmacol Hung. 2014 Mar;16(1):19-28.

 

Catatonia was first described in the 19th century as a syndrome with motor, affective and behavioral symptoms. During the 20th century it was rather regarded as a rare motoric manifestation of schizophrenia and that classification has almost resulted in the disappearance of catatonia ...

Last Updated: 1 Apr 2014

Go To URL
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.
 

Author(s): Anna Szota, Ewa Ogłodek, Aleksander Araszkiewicz

Journal: Pharmacol Rep. 2013 ;65(2):279-87.

 

Neuroleptic malignant syndrome (NMS) is the most dangerous life-threatening complication of antipsychotic medication. It's development is connected with the blockade of dopaminergic transmission (D2 receptors) in the nigrostriatal system of the brain. Fever is one of the main symptoms ...

Last Updated: 7 Jun 2013

Go To URL
Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.
 

Author(s): Julie Langan, Daniel Martin, Polash Shajahan, Daniel J Smith

Journal:

 

"Neuroleptic malignant syndrome" (NMS) is a potentially fatal idiosyncratic reaction to any medication which affects the central dopaminergic system. Between 0.5% and 1% of patients exposed to antipsychotics develop the condition. Mortality rates may be as high as 55% and many risk ...

Last Updated: 17 Jan 2013

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
 

Status: Recruiting

Condition Summary: Rhabdomyolysis; Myopathy; Acute Renal Failure; Neuroleptic Malignant Syndrome

 

Last Updated: 30 Nov 2009

Go to URL
Mindfulness Based Intervention (MBI) on the Quality of Life and Non-Motor Symptoms (NMS) of Persons With Parkinson's Disease (PD)
 

Status: Recruiting

Condition Summary: Parkinson's Disease; Non-Motor Symptoms of Parkinson's Disease

 

Last Updated: 20 May 2013

Go to URL